Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: Virological breakthrough is also dependent on adherence to medication

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 9, 2011, Pages 1111-1117

  Kamezaki, Hidehiro ^a   Kanda, Tatsuo ^a   Wu, Shuang ^a   Nakamoto, Shingo ^a   Arai, Makoto ^a   Maruyama, Hitoshi ^a   Fujiwara, Keiichi ^a   Imazeki, Fumio ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Adherence; Entecavir; HBV; Resistant mutants; Virological breakthrough

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DNA SEQUENCE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HOSPITAL PATIENT; HUMAN; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VIRUS MUTATION;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; JAPAN; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUTATION; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

EID: 80051712879     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2011.584898     Document Type: Article

References (29)

1. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348-55.
2. Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology 2009;49(5 Suppl):S56-60.
3. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34(Suppl 1):S1-3. (Pubitemid 43197742)
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39. (Pubitemid 46374607)
5. Wu S, Fukai K, Imazeki F, Arai M, Kanda T, Yonemitsu Y, Yokosuka O. Initial virological response and viral mutation with adefovir dipivoxil added to ongoing lamivudine therapy in lamivudine-resistant chronic hepatitis B. Dig Dis Sci 2011; 56:1207-14.
6. Chen CJ, Yang H, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. (Pubitemid 43042691)
7. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86. (Pubitemid 43374518)
8. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011;54:12-18.
9. Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over two decades. J Gastroenterol Hepatol 2011; 26(Suppl 1):S138-43.
10. Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobayashi H, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol 2010;52:791-9.
11. Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010;40:1-7.
12. Wu S, Kanda T, Imazeki F, Arai M, Yonemitsu Y, Nakamoto S, et al. Hepatitis B virus e antigen downregulates cytokine production in human hepatoma cell lines. Viral Immunol 2010;23:467-76.
13. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999;80:97-112. (Pubitemid 29248907)
14. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38: 518-26. (Pubitemid 36919874)
15. Ishibashi H, Maruyama H, Takahashi M, Fujiwara K, Imazeki F, Yokosuka O. Assessment of hepatic fibrosis by analysis of the dynamic behavior of microbubbles during contrast ultrasonography. Liver Int 2010;30:1355-63.
16. Kanda T, Jeong SH, Imazeki F, Fujiwara K, Yokosuka O. Analysis of 5¢ nontranslated region of hepatitis A viral RNA genotype I from South Korea: comparison with disease severities. PLoS One 2010;5:e15139.
17. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14.
18. Seta T, Yokosuka O, Imazeki F, Tagawa M, Saisho H. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 2000;60:8-16.
19. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006;44:703-12. (Pubitemid 44433727)
20. Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, et al. Two cases of development of entecavir resistance during entecavir treatment for nucleotide-naïve chronic hepatitis B. Hepatol Int 2009;3: 403-10.
21. Mukaide M, Tanaka Y, Shin-I T, Yuen MF, Kurbanov F, Yokosuka O, et al. Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. Antimicrob Agents Chemother 2010;54:882-9.
22. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19-26. (Pubitemid 36042140)
23. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011;26 (Suppl 1):123-30.
24. Luire Y, Manns MP, Gish RG, Chang TT, Yurdaydin C, Lai CL, et al. The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naïve, HBeAg(+) and HBeAg(-) patients with chronic hepatitis B. J Hepatol 2005;42(Suppl 2):184.
25. Odegard PS, Gray SL. Barriers to medication adherence in poorly controlled diabetes mellitus. Diabetes Educ 2008;34: 692-7.
26. Hill MN, Miller NH, Degeest S, American Society of Hypertension Writing Group, Materson BJ, Black HR, et al. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens 2011;5: 56-63.
27. Becker BW, Thames AD, Woo E, Castellon SA, Hinkin CH. Longitudinal change in cognitive function and medication adherence in HIV-infected adults. AIDS Behav 2011; Epub ahead of print.
28. El-Khatib Z, Ekstrom AM, Coovadia A, Abrams EJ, Petzold M, Katzenstein D, et al. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa-a prospective cohort study. BMC Public Health 2011;11:88.
29. Ha NB, Ha NB, Garcia RT, Trinh HN, Chaung KT, Nguyen HA, et al. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci 2011; [Epub ahead of print].